The ROIC-ROE spread tells the leverage story: as debt-to-equity fell from 0.73 to 0.39 and total debt declined about 41% from its 2024Q2 peak, ROE actually improved to 5.5% in 2026Q2, meaning the return lift came from margin expansion rather than financial engineering. However, with asset turnover stuck in a narrow 0.31-0.38 band for two years, the efficiency engine that would normally drive ROIC higher on a shrinking asset base (net PPE down ~85%) has not engaged, leaving investors dependent entirely on continued operating margin gains to reach a defensible cost of capital. The single-quarter ROIC of 4.1% in 2025Q4 matching 2026Q2's 3.9% suggests the ceiling may be structural rather than cyclical.

The margin structure suggests genuine operating leverage: prior statement analysis shows SG&A rose only ~17% while gross profit climbed ~30% over eight quarters, so the operating income swing from -$845K to $4.2M is driven by cost flatness, not one-time items. The recurring first-quarter weakness (2025Q1 operating margin of 1.8%, 2026Q1 of 4.7%) appears seasonal, likely tied to insurance deductible resets that suppress elective infusion volumes, which means annualized run-rate estimates based on any single quarter will carry material error. Net margin of 8.7% in 2026Q2 flatters true earning power given stock-based compensation of roughly $1.2M per quarter equals about 38% of that quarter's net income; on a cash-compensation-adjusted basis, the sustainable margin is meaningfully lower and should anchor any multiple applied to the business.

The quick ratio sitting within 0.36x of the current ratio confirms inventory is a minor balance sheet component, so the entire liquidity buffer is a $63-day DSO receivables book — collectible, but slow to convert under stress. In a scenario where major payor counterparties delayed reimbursement by even two weeks, the company's cash cushion would be exhausted before receivables could replenish it, implying reliance on the credit facility for working capital bridging. The current ratio's climb from 1.80 to 2.50 across the window reads as deleveraging progress, but investors should monitor the cash line rather than the headline ratio, since the composition of current assets matters more than the aggregate for a business this size with this receivables intensity.

The forward P/E of 30.02 and forward EV/EBITDA of 9.93 imply the market expects earnings to grow into the multiple, but this rests on operating margin holding near the 10-11% zone rather than reverting to the 2025Q1-type seasonal dips that dragged net margin negative. Compared to Healthcare Services Group at 31x P/E with a 20.2% ROE and 9.0% ROIC, InfuSystem's 5.5% ROE and 3.9% ROIC offer materially lower return on the capital being purchased, so the valuation gap versus higher-quality compounders in the peer set appears difficult to justify on current return metrics alone. The 11.06x EV/EBITDA is the more defensible entry point if the D&A-heavy capital structure (with net PPE having collapsed ~85%) means EBITDA overstates true distributable cash economics less than it would for a heavier-asset peer.

The 63-day DSO against a 55-day DPO means the company collects roughly eight days slower than it pays suppliers, a modest but persistent drag that has widened from a 5-day gap in 2024Q1, which may signal either payor mix shifts toward slower-reimbursing commercial plans or looser collection discipline warranting further investigation. The asset turnover improvement from 0.31 to 0.38 is mechanically inflated by the ~85% reduction in net PPE rather than by revenue growth, which decelerated to 2.6% in 2026Q2, so the efficiency trend overstates underlying operating velocity. With CCC fluctuating in a narrow band despite the balance sheet restructuring, the working capital profile appears operationally steady, meaning incremental cash generation depends more on the capex retreat (from 22.7% to 0.2% of revenue) than on any structural working capital improvement.